TGFB1 and head and neck squamous cell carcinoma: However, this study shows that a baseline level of circulating TGF-β over the identified threshold, is an unfavorable prognostic marker in patients with HNSCC that are treated with immunotherapy, which is an aspect not yet reported in the literature [55].